Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CytomX Therapeutics, Inc. (CTMX)
|
Add to portfolio |
|
|
|
| Price: |
$4.49
| | Metrics |
| OS: |
66.8
|
M
| |
|
|
| Market cap: |
$300
|
M
| |
-148
|
% ROIC
|
|
Net cash:
|
$181
|
M
| |
$2.71
|
per share
|
|
EV:
|
$119
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($18.0)
|
M
| |
|
|
| EPS |
($0.13)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 53.2 | 164.8 | 37.3 | 151.5 | 68.4 | 26.9 | 59.5 | 71.6 |
| Revenue growth | 42.5% | 8.8% | -45.5% | | 154.4% | -54.8% | -16.9% | 376.1% |
| Cost of goods sold | 0.0 | 154.5 | 0.0 | 153.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 53.2 | 10.3 | 37.3 | -1.8 | 68.4 | 26.9 | 59.5 | 71.6 |
| Gross margin | 100.0% | 6.3% | 100.0% | -1.2% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 154.5 | | 153.4 | | 149.0 | 168.4 | | |
| Research and development | | | | | | | 103.9 | 92.3 |
| General and administrative | | 42.8 | | 39.2 | | | 33.5 | 25.6 |
| EBITA | -101.4 | -101.3 | -115.9 | -116.0 | -80.4 | -141.3 | -77.7 | -46.1 |
| EBITA margin | -190.8% | -61.5% | -310.6% | -76.6% | -117.5% | -525.4% | -130.6% | -64.4% |
| Amortization of intangibles | 0.1 | | 0.1 | | 0.1 | 0.1 | 0.1 | 0.1 |
| EBIT | -101.6 | -101.3 | -116.0 | -116.0 | -80.5 | -141.5 | -77.9 | -46.3 |
| EBIT margin | -191.1% | -61.5% | -311.0% | -76.6% | -117.7% | -525.9% | -130.9% | -64.6% |
| Pre-tax income | -99.3 | -99.3 | -115.9 | -115.9 | -78.7 | -133.3 | -70.3 | -43.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -13.9 | -0.4 | 14.3 | -0.5 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 17.7% | 0.3% | | 1.2% |
| Net income | -99.3 | -99.3 | -115.9 | -115.9 | -64.8 | -132.8 | -84.6 | -43.1 |
| Net margin | -186.8% | -60.3% | -310.5% | -76.5% | -94.7% | -493.7% | -142.2% | -60.2% |
| |
| Diluted EPS | ($1.51) | ($1.51) | ($1.81) | ($1.81) | ($1.40) | ($2.93) | ($2.03) | ($1.16) |
| Shares outstanding (diluted) | 65.7 | 65.7 | 64.1 | 64.1 | 46.1 | 45.3 | 41.7 | 37.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|